Halozyme prices upsized $1.3B convertible note offering
What's the deal? Halozyme Therapeutics has priced an upsized private offering of $1.3 billion in convertible senior notes due 2033. The San Diego biopharmaceutical company (NASDAQ: HALO) had originally planned to raise $1.05 billion but increased the size on strong investor demand.
The terms: The notes carry a 1.50% annual interest rate, payable semi-annually, and are senior, unsecured obligations. The initial conversion rate is 7.1509 shares per $1,000 in principal — a conversion price of roughly $139.84 per share, a 27.5% premium over the stock's recent close.
Where the money goes: Net proceeds should reach about $1.275 billion. Halozyme will spend roughly $162.5 million on capped call transactions designed to limit stock dilution on conversion, and plans to repurchase outstanding convertible notes due in 2027 and 2028.
Why now? The refinancing lets Halozyme retire nearer-term debt and reset its capital structure. The offering, restricted to qualified institutional buyers, is scheduled to close on September 22, 2026.
What's the endgame? Halozyme's flagship ENHANZE technology simplifies delivery of injected drugs, aiming to improve patient convenience and treatment adherence. It licenses the technology to partners including Roche and Pfizer.
What could go wrong? The company expects existing noteholders to hedge their positions, activity that could move the stock. Capped calls may soften dilution when notes convert, but market conditions can still swing.
The signal: At $1.3 billion, this ranks among the largest post-IPO convertible rounds in its sector and geography over the past four years, sitting in the top percentile of 199 comparable deals. It underscores how established biopharma firms are tapping convertible debt to refinance cheaply while equity markets stay receptive.
Read more: third-news.com
Image credit: Nick Smith
